Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Ptaszynska, Agata; Cohen, Samuel M; Messing, Edward M; Reilly, Timothy P; Johnsson, Eva; Johnsson, Kristina

Ptaszynska, Agata; Cohen, Samuel M; Messing, Edward M; Reilly, Timothy P; Johnsson, Eva; Johnsson, Kristina.

Afiliación

Ptaszynska A; Bristol-Myers Squibb, Princeton, NJ, USA. agata.ptaszynska@bms.com.
Cohen SM; University of Nebraska Medical Center, Omaha, NE, USA.
Messing EM; Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Reilly TP; Bristol-Myers Squibb, Princeton, NJ, USA.
Johnsson E; AstraZeneca, Mölndal, Sweden.
Johnsson K; AstraZeneca, Mölndal, Sweden.

Diabetes Ther ; 6(3): 357-75, 2015 Sep.

Article en En | MEDLINE | ID: mdl-26323372

Palabras clave

Bladder cancer; Dapagliflozin; Hematuria; SGLT2 inhibitor; Type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Idioma: En Revista: Diabetes Ther Año: 2015 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google